EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
NovaBay Pharmaceuticals, Inc. (NBY) had EBIT Margin of -241.07% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$0.52M |
|
$-1.29M |
|
$0.48M |
|
$0.04M |
|
$1.78M |
|
$-1.26M |
|
$-0.08M |
|
$-1.33M |
|
$-1.33M |
|
$-1.33M |
|
$-1.33M |
|
$-1.29M |
|
$-1.33M |
|
$-1.26M |
|
$-0.58M |
|
5.88M |
|
5.88M |
|
$-0.22 |
|
$-0.22 |
|
| Balance Sheet Financials | |
$2.90M |
|
$0.01M |
|
$0.59M |
|
$3.49M |
|
$1.45M |
|
-- |
|
$0.41M |
|
$1.85M |
|
$-2.68M |
|
$1.63M |
|
$1.63M |
|
6.01M |
|
| Cash Flow Statement Financials | |
$-6.16M |
|
-- |
|
$-3.20M |
|
$0.91M |
|
$2.70M |
|
$1.79M |
|
$0.01M |
|
$-4.82M |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.00 |
|
-- |
|
-- |
|
-- |
|
0.09 |
|
8.06% |
|
-241.07% |
|
|
EBIT Margin |
-241.07% |
-- |
|
-255.85% |
|
-248.18% |
|
$-6.16M |
|
-- |
|
-- |
|
-- |
|
0.15 |
|
-- |
|
1.42 |
|
63.57 |
|
49.68% |
|
-81.58% |
|
-38.23% |
|
-81.58% |
|
$0.27 |
|
$-1.05 |
|
$-1.05 |
|